Valuate Health Consultancy

Valuate attended AMCP's Precision Medicine Partnership Forum and had the privilege to moderate and guide solution-focused activities. It was an incredible opportunity to witness thought leaders across payers, LBMs, providers, patient advocates, and industry unite around breaking down barriers to timely biomarker testing. This forum exposed critical frictions in the health system that impede patient access to biomarker testing and life-saving treatments. It also reaffirmed our belief that by working together, we can make #PrecisionMedicine in #Oncology truly patient-centered. Empowering every stakeholder is key to accelerating value-driven access to personalized cancer care. We're proud to be part of this ongoing partnership in pursuit of lasting solutions. Stay tuned for exciting updates on our next steps in the near future! Read AMCP's five key takeaways here: https://lnkd.in/ej9YMmHm #marketaccess #pharma #biotech

In market access, delivering impactful, effective work means embracing complexity and showing up with fearless excellence. Today, Connie Karambelas, SVP, Head of Creative, shares how Entrée Health turns complexity into clarity and creativity into access. #marketaccess #strategiccreativity #pharma #biotech #pov

In market access, a different kind of creative DNA is required—one that turns mountains of data into compelling clarity for payers. Learn how strategic creativity transforms constraints into pathways to access. Stay tuned for the full POV tomorrow! #marketaccess #strategiccreativity #pharma #biotech #POV

🚨 New POV Drop: ASCO 2025 – A Cross-Network Take from Omnicom Health Omnicom Health showed up in full force at ASCO 2025, with attendees from across our network bringing a range of expertise—from science and strategy to access and engagement. In this latest thought leadership piece, we tapped into four of those voices, each offering a distinct perspective on the biggest conversations shaping oncology’s future: 🔬 Brenda Aske, RPh (Biolumina) – Precision science and brand storytelling 🤖 Steve Mason, Ph.D. (Healthcare Consultancy Group - HCG) – AI and trust in clinical decisions 🗣️ Aishah S. (TBWA\WORLDHEALTH) – Patient agency and equitable care 📈 John Hennessy (Valuate Health Consultancy) – Policy, access, and real-world impact Together, these reflections showcase the power of cross-network thinking—and how we’re living our belief: Uniquely Powerful, Together Unstoppable. 🔔 Want to stay in the know? Subscribe to The Next Big Thing: www.bethecasestudy.com #OmnicomHealth #ASCO2025 #ThoughtLeadership #OncologyMarketing #TogetherUnstoppable #TheNextBigThing #HealthcareStrategy #InnovationInOncology

Valuate Health Consultancy is privileged to be working with AMCP on initiatives like the Precision Medicine Partnership Forum. Aimed at finding solutions to improve access and quality in precision #oncology, our recent session explored topics including: alignment to guidelines for easier adoption; standardizing the terminology used across the PM ecosystem; and driving collaboration to boost uptake of biomarker testing. We’re looking forward to next steps at Nexus 2025 and AMCP 2026 and from continued work by partners like National Comprehensive Cancer Network® (NCCN®), Association of Cancer Care Centers, Association for Molecular Pathology (AMP), and American Society for Clinical Pathology (ASCP). #marketaccess #pharma #biotech https://lnkd.in/eySUNNkz

Coverage doesn’t always equal access. In his ASCO 2025 recap, John Hennessy breaks down why the future of cancer care will require a shift from thinking fast to thinking slow, and what that means for #marketaccess in a rapidly evolving environment. #asco #asco205 #oncology #pharma #biotech

The #raredisease market has seen incredible growth, and with advances in cutting-edge technologies, payers are beginning to treat the rare space like any other treatment area. Today, Lori Wood breaks down what this shift means and how to navigate this new landscape. #rareisntrare #marketacccess #pharma #biotech

The rare disease market has seen incredible growth, and with advances in cutting-edge technologies, payers are beginning to treat the rare space like any other treatment area. This has pharma manufacturers wondering: how do we navigate this new landscape? Is your strategy built for what’s next? Stay tuned for a full breakdown from our expert, Lori Wood, on Wednesday. #marketaccess #raredisease #pharma #biotech

Another year at American Society of Clinical Oncology (ASCO), and our agency teams are grateful for the opportunity to connect, learn, and be inspired at #ASCO2025. The future of oncology is bright—and we’re energized to keep pushing boundaries for patients everywhere.   Full recap coming soon... 👀   #ASCO #Oncology #OmnicomHealth #TogetherUnstoppable

This year’s Vision Meeting brought together the momentum of the past year and the ambition of what’s ahead. We celebrated what sets us apart, reflected on the work that matters, and left even more committed to showing up with tenacity, impact, heart, and vision. Because at the core of it all, we believe everyone deserves access to the healthcare they need. Here’s to continuing to raise the bar through Fearless Excellence! #tenacity #impact #heart #vision #fearlessexcellence #visionmeeting #agencylife #marketaccess